Skip to main content
Premium Trial:

Request an Annual Quote

Aqualung Therapeutics Wins $225K NIH Grant to Develop Respiratory Distress Biomarker Panel

NEW YORK — Aqualung Therapeutics said on Tuesday that it has been awarded a $225,000 grant from the National Institutes of Health to develop a panel of biomarkers, called CRIT-ICU, for stratifying patients at risk for acute respiratory distress syndrome (ARDS).

With the funding, Aqualung said it will evaluate 11 previously identified ARDS-related plasma biomarkers — including cytokine-chemokines, dual-functioning cytozymes, vascular injury markers, and the advanced glycosylation end product pathway — to establish a panel that can predict intensive care unit (ICU) mortality in sepsis or trauma patients who are at risk for the condition.

The Tucson, Arizona-based firm, which is developing a monoclonal antibody-based treatment for acute respiratory failure, said it will then create a standardized platform for CRIT-ICU for use in a clinical setting, as well as perform retrospective validation studies of the panel in biobanked samples. 

"We will aim to apply standard biostatistical approaches, as well as a novel neural network of artificial intelligence, to help identify an optimal plasma derived biomarker panel [that] predicts ICU mortality," Aqualung Founder and CEO Joe Garcia said in a statement. "The goal of this CRIT-ICU panel is to identify patients at risk for ARDS and lead to the development of a true point-of-care test to accelerate clinical trial stratification strategies, and the development of innovative ARDS therapeutics to reduce mortality in this devastating syndrome."

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.